SAT-489 Cardiovascular Risk Factors In Non-Functioning Pheochromocytoma And Paraganglioma: A Cross-Sectional Study

Abstract Disclosure: C. Ramirez-Renteria: None. P.E. Espinosa Cardenas: None. A. Albarran: None. N.G. Lopez-Juarez: None. G.R. Manuel: None. E. Sosa: None. Background: Preoperative management with alpha or beta blockade in non-functioning pheochromocytomas (Pheo) and paragangliomas (para) remains controversial, but the pre-anaesthetic evaluation should assess all the cardiovascular risk (CVR) factors that may be present even in young patients. Aim: to describe the frequency of CVR factors in patients evaluated for non-functioning Pheo and PGN in a referral centre. Materials and methods: All the medical files of adult patients evaluated for Pheo or PGN between January 2018 and March 2025. were reviewed. We determined the frequency of traditional CVR factors and previous cardiovascular events in patients with negative hormonal tests and enough clinical information. Results: From a database of 534 patients, 165 fulfilled the inclusion criteria (we excluded 15 from a different referral centre, 39 functioning tumours, and 315 without laboratory test results). Most (91.5%) were women, with a median age of 59 years (IQR 49-68), and 83% were in the carotid body. A previous diagnosis of hypertension was present in 55.2%, and 20% were using beta blockers at the time of diagnosis. Hyperlipidemia was present in 56.1%, previous heart disease in 21.3%, prediabetes in 36.4%, diabetes in 21.8% and active tobacco use in 16.9%. Median total lipids (in mg/dL) were 171 for cholesterol (normal <200), HDL was 46 mg/dL, LDL 99 (<100) and triglycerides 123 (<150). During surgery, 31.4% had elevated blood pressure and 28.2% hypotension, 15.5% required drugs or fluids to stabilize their blood pressure, 11 patients had a cerebrovascular event after the surgery (one died) and 1 had an ischemic cardiac event. Conclusions: Patients with non-functioning Pheo/PGN have a high frequency of comorbidities related to cardiovascular disease. Proper assessment and treatment may help reduce the risk of intraoperative complications. Thorough evaluation, including hormone testing, is suggested in all patients with Pheo/para before surgery. Presentation: Saturday, July 12, 2025